Show Summary Details
Page of

Current status of GP IIb/IIIa inhibitors 

Current status of GP IIb/IIIa inhibitors
Chapter:
Current status of GP IIb/IIIa inhibitors
Author(s):

Tim Lockie

and Simon Redwood

DOI:
10.1093/med/9780199569083.003.023
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 16 February 2020

The process of atheromatous plaque rupture is thought to underlie most acute coronary syndromes (ACS) and thus is a major cause of overall morbidity and mortality. As a result, the costs in terms of healthcare expenditure of the consequences of acute plaque rupture are considerable. The immediate and often catastrophic result of plaque rupture is intracoronary thrombosis resulting in vessel occlusion and myocardial infarction (MI). Over the last 20 years there has been a steady decline in the mortality rates from ACS that has resulted from the successful implementation of therapies to attenuate the effects of plaque rupture that include fibrinolysis, percutaneous revascularization, antithrombotic therapy, and plaque stabilization. Glycoprotein (GP) IIb/IIIa receptor inhibitors are agents that have been developed to block the final common pathway that results in platelet aggregation, and following plaque rupture is a key process in coronary thrombosis. Despite the improvement in outcomes from ACS, however, the mortality rate still remains high and there is a need for critical appraisal of the use of currently available agents as well as the need for ongoing research and development of new agents and clinical techniques to improve outcomes further.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.